Data gathered: November 24
Alternative Data for Hookipa Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 70 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 70 | Sign up | Sign up | Sign up |
| Google Trends | 4 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 9 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,247 | Sign up | Sign up | Sign up |
| Twitter Followers | 727 | Sign up | Sign up | Sign up |
| Twitter Mentions | 91 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 120 | Sign up | Sign up | Sign up |
About Hookipa Pharma
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.
| Price | $2.15 |
| Target Price | Sign up |
| Volume | 92,820 |
| Market Cap | $26M |
| Year Range | $2.15 - $10.4 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Hookipa Pharma price target lowered to $7 from $24 at JMP SecuritiesNovember 21 - Yahoo |
 |
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec programNovember 21 - Yahoo |
 |
Hookipa Pharma stock hits 52-week low at $2.62 amid market challengesNovember 21 - Investing.com |
 |
Royal Bank of Canada Has Lowered Expectations for Hookipa Pharma (NASDAQ:HOOK) Stock PriceNovember 16 - ETF Daily News |
 |
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite RiskyNovember 16 - Yahoo |
 |
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 16 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 4.7M | 7.8M | -3.1M | -14M | -19M | -1.100 |
| Q2 '24 | 1.3M | 4M | -2.7M | -19M | -18M | -1.520 |
| Q1 '24 | 37M | 5.3M | 31M | 14M | 13M | 0.110 |
| Q4 '23 | 7.4M | 17M | -9.8M | -25M | -23M | -0.220 |
| Q3 '23 | 6.8M | 4.9M | 1.9M | -19M | -23M | -0.170 |
Insider Transactions View All
| Kandera Reinhard filed to buy 43,092 shares at $0.7. August 22 '23 |
| Kandera Reinhard filed to buy 36,092 shares at $0.7. August 17 '23 |
| Aldag Jorn filed to buy 71,952 shares at $0.8. July 11 '23 |
| Aldag Jorn filed to buy 61,952 shares at $0.9. July 7 '23 |
| Aldag Jorn filed to buy 56,952 shares at $0.9. July 5 '23 |
Similar companies
Read more about Hookipa Pharma (HOOK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Hookipa Pharma?
The Market Cap of Hookipa Pharma is $26M.
What is the current stock price of Hookipa Pharma?
Currently, the price of one share of Hookipa Pharma stock is $2.15.
How can I analyze the HOOK stock price chart for investment decisions?
The HOOK stock price chart above provides a comprehensive visual representation of Hookipa Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Hookipa Pharma shares. Our platform offers an up-to-date HOOK stock price chart, along with technical data analysis and alternative data insights.
Does HOOK offer dividends to its shareholders?
As of our latest update, Hookipa Pharma (HOOK) does not offer dividends to its shareholders. Investors interested in Hookipa Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Hookipa Pharma?
Some of the similar stocks of Hookipa Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.